Handelsbanken Fonder’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Handelsbanken Fonder’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-18,000	Closed	-$363K	–	1777
2021 Q3	$363K	Buy	18,000 +6,000	+50%	+$166K	﹤0.01%	1527
2021 Q2	$448K	Buy	12,000 +700	+6%	+$21.5K	﹤0.01%	1457
2021 Q1	$289K	Hold	11,300	–	–	﹤0.01%	1461
2020 Q4	$249K	Hold	11,300	–	–	﹤0.01%	1470
2020 Q3	$203K	Hold	11,300	–	–	﹤0.01%	1383
2020 Q2	$287K	Buy	+11,300	New	+$243K	﹤0.01%	1243

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Handelsbanken Fonder's DRNA Position: Q4 2021 in Review

Handelsbanken Fonder sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 18,000 shares — an estimated $363K sold.

Handelsbanken Fonder first reported a position in DRNA in Q2 2020 and held it in 6 quarters. The position peaked at $448K in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Handelsbanken Fonder reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Handelsbanken Fonder sold 18,000 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $363K.
Handelsbanken Fonder first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2020 and held it in 6 quarters.
Handelsbanken Fonder's Dicerna Pharmaceuticals, Inc. position peaked at $448K in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Handelsbanken Fonder's 13F filing for Q4 2021, filed 8 Feb 2022.